Structured Abstract
Objectives The drivers of antimicrobial resistance (AMR) likely vary substantially by diKerent demographics. However, few complete open national detailed data exist on how antibiotic use (ABU) varies by both age and sex.
Methods Here, prescriptions of antibiotics from General Practices in England for 2015-2023 disaggregated by 5-year age bands and sex were analysed at the national and Integrated Care Board (ICB) level. From a total of 249,578,795 prescriptions (across 9 years), 63% were given to women and the most prescribed were amoxicillin, nitrofurantoin and flucloxacillin sodium. Prescriptions per 100K population varied substantially across sex, age, geographical region, season, year, COVID-19 pandemic period and drug.
Results Most antibiotics were prescribed more to women across most age bands (84% of antibiotics had more prescriptions to females across 50% of age bands). We show how this variation requires a more nuanced approach to comparing ABU across geographies and highlight that AWaRe targets are not met uniformly (young men have a higher proportion of “Watch” antibiotic prescriptions). We also show the impact on ABU of time-sensitive interruptions, including diKerential age-targeted influenza vaccination, COVID-19 restrictions and a shortage of amoxicillin combined with a Streptococcus A outbreak. Comparing to open access AMR data (MRSA in bloodstream infections) highlights the complexity of the link between ABU and AMR.
Conclusions These detailed diKerences in ABU across England suggest that there should be large variation in AMR burden by age and sex, which now need to be quantified with detailed open access AMR data for a better intervention design.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
GMK and NRW were supported by the Medical Research Council UK, https://www.ukri.org/opportunity/career-development-award/ (MR/W026643/1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study only uses data that are publically available through Freedom of Information Requests. FOI-01671 and FOI-01975 - Open Data Portal BETA. https://opendata.nhsbsa.net/dataset/foi-01671 and https://opendata.nhsbsa.net/dataset/foi-01975
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
